Angion’s HGF Mimetic Fails Second Phase II Study, But Not Shuttered Yet

Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.